Tamez-Péreza HE

Language: Spanish
References: 20
Page: 142-148
PDF size: 258.15 Kb.

ABSTRACT

Background: Diabetes mellitus type 2 (DM2) is a multifactorial disease that can be treated with oral antiglycemic medication or with insulin. The antiglycemic drugs glimepiride and sitagliptin have different mechanisms of action, and have not been directly compared in a Latin-American population with recent DM2 diagnostic.
Methods: The primary objective in this randomized (1:1), multicentric, two arms, open study with adult patients, was to compare the effi cacy of glimepiride with sitagliptin in a DM2 population naïve to treatment. Secondary objectives had been the effect on fasting and postprandial glycemia, hypoglycemia, weight modifi cation, safety, percentage of patients quiting the trial, vital signs and laboratory results.
Results: Glimepiride and sitagliptin were equally effective in glycemic control and all other parameters, and the only difference found has been the frequency of hypoglycemic events reports, wich has been reported as higher and statistically significant in the in the glimepiride group. No fatalities where reported in either group.
Conclusions: Glimepiride or sitagliptin monotherapy are equally effective in control of HbA1c.

REFERENCES

1. DeFronzo RA. Pathogenesis of type 2 diabetes mellitus. Med. Clin. North Am. 2004;88(4):787-835.

2. Word Health Organization. Diabetes program [Internet]. Switzerland:WHO; [citado 14 Oct 2013] Disponible en http://www.who.int/diabetes/en/

3. Hernández-ávila M, Gutiérrez JP, Reynoso-Noverón N. Diabetes mellitus en México . El estado de la epidemia. Salud Publica Mex. 2013;55(1):129-36.

4. Secretaría de Salud.Estadísticas de mortalidad. Sistema Nacional de Información en salud 2005 [Internet]. México: Secretaría de Salud; [Citado14 Oct]. Disponible en http://sinais.salud.gob.mx/mortalidad/

5. Secretaría de Salud. Anuarios de morbilidad 1984- 2006 [Internet] México: Secretaría de Salud-Dirección General de Epidemiología SS [citado 14 Oct 2013]. Disponible en http://www.dgepi.salud.gob.mx/ anuario/index.html

6. UKPDS Group. UK prospective diabetes study 7: Response of fasting plasma glucose to diet therapy in newly presenting type II diabetic patients,UKPDS Group. Metabolisim. 1990;39(9):905-12

7. Davis S. The role of glimepiride in the effective management of Type 2 diabetes. J Diabetes Complications. 2004;18(6):367-76.

8. Campbell R. Glimepiride: role of a new sulfonylurea in the treatment of type 2 diabetes mellitus. Ann. Pharmacother. 1998;32(10):1044-52

9. Yamanouchi T, Sakai T, Igarashi K, Ichiyanagi K, Watanabe H, Kawasaki T. Comparison of metabolic effects of pioglitazone, metformin, and glimepiride over 1 year in Japanese patients with newly diagnosed Type 2 diabetes. Diabet Med. 2005;22(8):980-5. 148 Rev Med Inst Mex Seguro Soc. 2015;53(2):142-8 Tamez-Pérez HE et al. Glimepirida versus sitagliptina en diabetes mellitus tipo 2

10. Drucker DJ, Nauck M. The incretin system: glucagon- like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006;368(9548):1696-705.

11. Amori RE, Lau J, Pittas AG. Effi cacy and safety of incretin therapy in type 2 diabetes systematic review and meta-analysis. JAMA. 2007;298(2):194-206.

12. Gadsby R. effi cacy and safety of sitagliptin in the treatment of type 2 diabete:s pharmacology of sitagliptin. Clin Med. 2009;1:53-62.

13. Word Health Organization. Use of glycated haemoglobin (HbA1c) in the diagnosis of diabetes mellitus Abbreviated report of a WHO consultation[Internet]. Switzerland:WHO; 2011 [citado 14 Oct 2013]. Disponible en www.who.int/diabetes/publications/reporthba1c_ 2011.pdf

14. BennettCM, Guo M, Dharmage SC. HbA1c as a screening tool for detection of Type 2 diabetes: a systematic review. Diabet Med. 2007;24(4):333-43.

15. Inzucchi SE, Bergenstal RM, Buse JB, et al.; American Diabetes Association (ADA), European Association for the Study of Diabetes (EASD). Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012;35(6):1364-79.

16. Tamez-Pérez HE, Proskauer-Peña SL, Hernŕndez- Coria MI, Garber AJ. AACE Comprehensive Diabetes Management Algorithm 2013. Endocrine Practice. Endocr Pract. 2013;19(4):736-7.

17. Raz I, Hanefeld M, Xu L, Caria C, Williams-Herman D, Khatami H. Effi cacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. Diabetologia. 2006;49(11):2564-71.

18. Goldberg R, Holvey S, Schneider J. A dose-response study of glimepiride in patients with NIDDM who have previously received sulfonylurea agents. The Glimepiride Protocol #201 Study Group. Diabetes Care. 1996;19(8):849-56.

19. Weitgasser R, Lechleitner M, Luger A, Klingler A. Effects of glimepiride on HbA1c and body weight in Type 2 diabetes: results of a 1.5-year follow-up study. Diabetes Res Clin Pract. 2003;61(1):13-9.

20. Aschner P, Kipnes M, Lunceford J, Sanchez M, Mickel C, Williams-Herman D. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2. Diabetes Care. 2006;29(12):2632-7.